| 000 | 01661 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250515181312.0 | ||
| 264 | 0 | _c20090930 | |
| 008 | 200909s 0 0 eng d | ||
| 022 | _a1442-9071 | ||
| 024 | 7 |
_a10.1111/j.1442-9071.2009.02061.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPark, Sung P | |
| 245 | 0 | 0 |
_aChanges of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. _h[electronic resource] |
| 260 |
_bClinical & experimental ophthalmology _cJul 2009 |
||
| 300 |
_a490-5 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAqueous Humor _xmetabolism |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
| 650 | 0 | 4 |
_aEye Proteins _xmetabolism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMacular Edema _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNerve Growth Factors _xmetabolism |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aRetinal Vein Occlusion _xcomplications |
| 650 | 0 | 4 |
_aSerpins _xmetabolism |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 700 | 1 | _aAhn, Jae K | |
| 773 | 0 |
_tClinical & experimental ophthalmology _gvol. 37 _gno. 5 _gp. 490-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1442-9071.2009.02061.x _zAvailable from publisher's website |
| 999 |
_c19033090 _d19033090 |
||